Patent Application
20050256324
A number of compounds that are generally useful as inhibitors of enzymes having a nucleophilic group at the N-terminus have been identified that are structurally related to epoxomicin (Hanada, M., et al. (1992) J. Antibiotics, 45(11): 1746-1752). These compounds are described in U.S. patent application Ser. Nos. 09/569748, 60/562340, 11/106,879, and the PCT filed on May 9, 2005 and are hereby incorporated by reference in their entirety.
There remains a need for an improved process for the production of these compounds in an efficient manner.
This invention relates to methods for the synthesis of amino acid keto-epoxides according to scheme (I)
wherein
Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
A number of compounds that are generally useful as inhibitors of enzymes having a nucleophilic group at the N-terminus have been identified. The invention describes efficient methods for the production of these compounds. More specifically, described herein are methods for the stereoselective synthesis of amino acid keto-epoxides.
These keto-epoxides may optionally include groups bonded to α′ carbons, the stereochemistry of the α′-carbon (that carbon forming a part of the epoxide or aziridine ring) can be (R) or (S). Note that a preferred compound may have a number of stereocenters having the indicated up-down (or ⊖-α, where β as drawn herein is above the plane of the page) or (R)—(S) relationship (that is, it is not required that every stereocenter in the compound conform to the preferences stated). In some preferred embodiments, the stereochemistry of the α′ carbon is (R), that is, the X atom is β, or above the plane of the molecule. Regarding the stereochemistry, the Cahn-Ingold-Prelog rules for determining absolute stereochemistry are followed. These rules are described, for example, in Organic Chemistry, Fox and Whitesell; Jones and Bartlett Publishers, Boston, Mass. (1994); Section 5-6, pp 177-178, which section is hereby incorporated by reference.
This invention relates to methods for the synthesis of amino acid keto-epoxides according to scheme (I)
wherein
The use of various N-protecting groups, e.g., the benzyloxy carbonyl group or the t-butyloxycarbonyl group (Boc), various coupling reagents, e.g., dicyclohexylcarbodiimide (DCC), 1,3-diisopropylcarbodiimide (DIC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC), N-hydroxyazabenzotriazole (HATU), carbonyldiimidazole, or 1-hydroxybenzotriazole monohydrate (HOBT), and various cleavage conditions: for example, trifluoracetic acid (TFA), HCl in dioxane, hydrogenation on Pd-C in organic solvents (such as methanol or ethyl acetate), boron tris(trifluoroacetate), and cyanogen bromide, and reaction in solution with isolation and purification of intermediates are well-known in the art of peptide synthesis, and are equally applicable to the preparation of the subject compounds (Greene, T. W.; Wuts, P. G. M. Protective Groups in Organic Synthesis, 3rd ed.; Wiley: N.Y., 1999).
In certain embodiments, R1 is selected from a protecting group or a further chain of amino acids, which itself may be optionally substituted. In preferred embodiments, R1 is a protecting group. In a more preferred embodiment, R1 is an electron withdrawing protecting group. In certain such embodiments, R1 is selected from t-butoxy carbonyl (Boc), benzoyl (Bz), fluoren-9-ylmethoxycarbonyl (Fmoc), trichloroethoxycarbonyl (Troc), and benzyloxy carbonyl (Cbz). In the most preferred embodiment, R1 is Cbz.
In certain embodiments, R1 and R2 together are C(O)-aryl-C(O) or C(O)C1-6alkenylC(O), thereby forming a ring. In a preferred such embodiment, R1 and R2 together are phthaloyl.
In certain embodiments, R3 is selected from hydrogen, C1-6alkyl, C1-6alkoxyalkyl, heterocyclyl, aryl, heteroaryl, C1-6heteroaralkyl, and C1-6aralkyl. In preferred embodiments, R3 is C1-6alkyl. In the most preferred embodiment, R3 is isobutyl.
A is a stereoselective reduction under reducing conditions. In a preferred embodiment, the reducing agent in A is selected from sodium borohydride with cerium trichloride, lithium tri-tert-butoxyaluminum hydride, or L-selectride. In a more preferred embodiment, the reducing agent is sodium borohydride with cerium trichloride. Other suitable agents include, but are not limited to achiral reducing agents such as lithium aluminum hydride, trimethoxylithium aluminum hydride, K-selectride, KS-selectride, LS-selectride, and diisobutylaluminum hydride, chiral reducing agents such as (R) or (S)-2-methyl-CBS-oxaborolidine and (R) or (S)-alpine borane, chiral oxazaborolidines, (R,R or S,S) lithium dimethylborolane, and chiral alkoxy(acyloxy)borohydrides, or achiral reducing agents in the presence of chiral additives such as lithium aluminum hydride in the presence of quinine or ephedrine.
B is a stereoselective epoxidation under epoxidizing conditions. In preferred embodiments, the conditions include m-chloroperbenzoic acid (or another suitable peroxyacid) or VO(acac)2 with t-BuOOH. In the most preferred embodiment B is VO(acac)2 with t-BuOOH. Other suitable epoxidizing conditions include, but are not limited to, Sharpless asymmetric epoxidation, Shi asymmetric epoxidation, Jacobsen epoxidation, dimethyldioxirane, and trifluoromethylmethyldioxirane.
C is an oxidation under oxidizing conditions. In preferred embodiments, C is a Swern or Moffat oxidation or employs Dess-Martin periodinane or TPAP with NMO. In the most preferred embodiment, C is a Swern oxidation. Other suitable oxidizing agents include, but are not limited to, ruthenium dioxide, pyridinium chlorochromate (PCC), IBX, and pyridinium dichromate (PDC).
In certain embodiments, the invention provides the sequence of reactions as discrete steps, wherein the product of each reaction (A, B, and C) is isolated and purified. In another embodiment, the invention provides the sequence of reactions, wherein the product of at least one reaction is used in the next reaction without isolation and/or purification. Additionally, the invention relates to the sequence of reactions (A, B, and C), each individual reaction (A, B, and C) and subcombinations thereof. Thus, the invention relates to the synthesis of an allyl alcohol according to scheme (II)
wherein
The invention further relates to the synthesis of an epoxide according to scheme (III)
wherein
Additionally, the invention relates to the synthesis of arino acid keto-epoxides according to scheme (IV)
wherein
In another embodiment, the reduction may be replaced by an organometal addition to an aldehyde, followed by an epoxidation oxidation sequence as shown in scheme (V)
Alternatively, the epoxidation could be replaced with an asymmetric dihydroxylation, selective silylation or tosylation, epoxidation sequence as shown in scheme (VI) to arrive at the desired amino acid keto-epoxide.
In some embodiments, the amino acid keto-epoxide may optionally be further modified in a four-step procedure (Wipf, P. et al., 1998, J. Org. Chem., 63:6089-6090) or a 5 one-step procedure (Shao, H. et al., 1995, J. Org. Chem., 60:790-791) resulting in the formation of the corresponding aziridine.
In certain embodiments, the compounds in scheme I have the following stereochemistry
In certain embodiments, the amino acid keto-epoxide or keto-aziridine may be further modified by deprotection of the amine, if applicable, and coupling with a chain of amino acids. Methods for the coupling of such fragments are well known in the art (Elofsson, M., et al. (1999) Chemistry& Biology, 6:811-822; Elofsson, M., et al (1999) Chemistry& Biology, 6:811-822). In a preferred embodiment, the chain of amino acids comprises one to three amino acids.
In certain embodiments, the chain of amino acids has a structure of formula (I) or a pharmaceutically acceptable salt thereof
In some embodiments, R5, R6, and R7 are selected from C1-6alkyl or C1-6aralkyl. In preferred embodiments, R6 is C1-6alkyl and R5 and R7 are C1-6aralkyl. In the most preferred embodiment, R6 is isobutyl, R5 is 2-phenylethyl, and R7 is phenylmethyl.
In certain embodiments, L and Q are absent and R11 is selected from C1-6alkyl, C1-6alkenyl, C1-6-alkynyl, C1-6aralkyl, and C1-6heteroaralkyl. In certain such embodiments, R10 is C1-6alkyl and R11 is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
In other embodiments, L is SO2, Q is absent, and R11 is selected from C1-6alkyl and aryl. In certain such embodiments, R11 is selected from methyl and phenyl.
In certain embodiments, L is C═O and R11 is selected from C1-6alkyl, C1-6-alkenyl, C1-6alkynyl, aryl, C1-6aralkyl, heteroaryl, C1-6heteroaralkyl, R15ZA-C1-8alkyl-, R18Z-C1-8alkyl-, (R15O)(R16O)P(═O)O—C1-8alkyl-, (R15O)(R16O)P(═O)O—C1-8alkyl-ZAZ-C1-8alkyl-, (R15O)(R16O)P(═O)O—C1-18alkyl-Z-C1-8alkyl-, R15ZA-C1-8alkyl-ZAZ-C1-8alkyl-, heterocyclylMZAZ-C1-8alkyl-, (R17)2N—C1-8alkyl-, (R17)3N+—C1-8alkyl-, heterocyclylM-, carbocyclylM-, R18SO2C1-8alkyl-, and R18SO2NH—, wherein each occurrence of Z and A is independently other than a covalent bond. In certain embodiments, L is C═O, Q is absent, and R11 is H.
In certain embodiments, R10 is C1-6alkyl, R11 is C1-6alkyl, Q is absent, and L is C═O. In certain such embodiments, R11 is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.
In other embodiments, L is C═O, Q is absent, and R11 is C1-6aralkyl. In certain such embodiments, R11 is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.
In other embodiments, L is C═O, Q is absent, R10 is C1-6alkyl, and R11 is aryl. In certain such embodiments, R11 is substituted or unsubstituted phenyl.
In certain embodiments, L is C═O, Q is absent or O, n is 0 or 1, and R11 is —(CH2)ncarbocyclyl. In certain such embodiments, R11 is cyclopropyl or cyclohexyl.
In certain embodiments, L and A are C═O, Q is absent, Z is O, n is an integer from 1 to 8 (preferably 1), and R11 is selected from R15ZA-C1-8alkyl-, R18Z-C1-8alkyl-, R15ZA-C1-8alkyl-ZAZ-C1-8alkyl-, (R15O)(R16O)P(═O)O—C1-8alkyl-ZAZ-C1-8alkyl-, (R15O)(R16O)P(═O)O—C1-8alkyl-Z-C1-8alkyl-, and heterocyclylMZAZ-C1-8alkyl-, wherein each occurrence of A is independently other than a covalent bond. In certain such embodiments, R7 is heterocyclylMZAZ-C1-8alkyl- where heterocyclyl is substituted or unsubstituted oxodioxolenyl or N(R12)(R13), wherein R12 and R13 together are C1-6alkyl-Y—C1-6alkyl, preferably C1-3alkyl-Y—C1-3alkyl, thereby forming a ring.
In certain preferred embodiments, L is C═O, Q is absent, n is an integer from 1 to 8, and R11 is selected from (R15O)(R16O)P(═O)O—C1-8alkyl-, (R17)2NC1-8alkyl, (R17)3N+(CH2)n—, and heterocyclyl-M-. In certain such embodiments, R11 is —C1-8alkylN(R17)2 or —C1-8alkylN+(R17)3, where R17 is C1-6alkyl. In certain other such embodiments, R11 is heterocyclylM-, where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.
In certain embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH and R11 is selected from C1-6alkyl, cycloalkyl-M, C1-6aralkyl, and C1-6heteroaralkyl. In other embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH, and R11 is C1-6alkyl, where C1-6alkyl is selected from methyl, ethyl, and isopropyl. In further embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH and R11 is C1-6aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH, and R11 is C1-6heteroaralkyl, where heteroaralkyl is (4-pyridyl)methyl.
In certain embodiments, L is absent or is C═O, and R10 and R11 together are C1-6alkyl-Y—C1-6alkyl, C1-6alkyl-ZA-C1-6alkyl, or C1-6alkyl-A, wherein each occurrence of Z and A is independently other than a covalent bond, thereby forming a ring. In certain preferred embodiments, L is C═O, Q and Y are absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L and Q are absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L is C═O, Q is absent, Y is selected from NH and N—C1-6alkyl, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L is C═O, Y is absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L and A are C═O, and R10 and R11 together are C1-2alkyl-ZA-C1-2alkyl. In another preferred embodiment, L and A are C═O and R10 and R11 together are C2-3alkyl-A.
In certain embodiments, the chain of amino acids has a structure of formula (III)
wherein
In certain embodiments, R5, R6, and R7 are each independently selected from C1-6alkyl, C1-6hydroxyalkyl, C1-6alkoxyalkyl, aryl, C1-6aralkyl, and R16DVKOC1-3alkyl- wherein at least one of R5 and R7 is R16DVKOC1-3alkyl-. In preferred embodiments, one of R5 and R7 is C1-6aralkyl and the other is R16DVKOC1-3alkyl-, and R6 is independently C1-6alkyl. In the most preferred embodiment, one of R5 and R7 is 2-phenylethyl or phenylmethyl and the other is R16DVKOCH2- or R16DVKO(CH3)CH—, and R6 is isobutyl.
In certain embodiments, each R15 is independently selected from hydrogen, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C1-6aralkyl, and C1-6heteroaralkyl.
In certain embodiments, each R19 is independently selected from hydrogen, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C1-6aralkyl, and C1-6heteroaralkyl.
In certain embodiments, L and Q are absent and R11 is selected from hydrogen, a further chain of amino acids, C1-6acyl, a protecting group, aryl, heteroaryl, C1-6alkyl, C1-6alkenyl, C1-6alkynyl, C1-6aralkyl, and C1-6heteroaralkyl. In certain such embodiments, R10 is C1-6alkyl and R11 is selected from butyl, allyl, propargyl, phenylmethyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
In other embodiments, L is SO2, Q is absent, and R11 is selected from C1-6alkyl and aryl. In certain such embodiments, R11 is selected from methyl and phenyl.
In certain embodiments, L is C═O and R11 is selected from C1-6alkyl, C1-6alkenyl, C1-6alkynyl, aryl, C1-6aralkyl, heteroaryl, C1-6heteroaralkyl, R12ZA-C1-8alkyl-, R15Z-C1-8alkyl-, (R12O)(R13O)P(═O)O—C1-8alkyl-, (R12O)(R13O)P(═O)O—C1-8alkyl-ZAZ-C1-8alkyl-, (R12O)(R13O)P(═O)O—C1-8alkyl-Z-C1-8alkyl-, R12ZA-C1-8alkyl-ZAZ-C1-8alkyl-, heterocyclylMZAZ-C1-8alkyl-, (R14)2N—C1-8alkyl-, (R14)3N+—C1-8alkyl-, heterocyclylM-, carbocyclylM-, R15SO2C1-8alkyl-, and R15SO2NH—. In certain embodiments, L is C═O, Q is absent, and R11 is H.
In certain embodiments, R10 is C1-6alkyl, R11 is C1-6alkyl, Q is absent, and L is C═O. In certain such embodiments, R11 is ethyl, isopropyl, 2,2,2-trifluoroethyl, or 2-(methylsulfonyl)ethyl.
In other embodiments, L is C═O, Q is absent, and R11 is C1-6aralkyl. In certain such embodiments, R11 is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.
In other embodiments, L is C═O, Q is absent, R10 is C1-6alkyl, and R11 is aryl. In certain such embodiments, R11 is substituted or unsubstituted phenyl.
In certain embodiments, L is C═O, Q is absent or O, and R11 is —(CH2)ncarbocyclyl. In certain such embodiments, R11 is cyclopropyl or cyclohexyl.
In certain embodiments, L and A are C═O, Q is absent, Z is O, and R11 is selected from R12ZA-C1-8alkyl-, R15Z-C1-8alkyl-, R12ZA-C1-8alkyl-ZAZ-C1-8alkyl-, (R12O)(R13O)P(═O)O—C1-8alkyl-ZAZ-C1-8alkyl-, (R12O)(R13O)P(═O)O—C1-8alkyl-Z-C1-8alkyl-, and heterocyclylMZAZ-C1-8alkyl-. In certain such embodiments, R11 is heterocyclylMZAZ-C1-8alkyl- where heterocyclyl is substituted or unsubstituted oxodioxolenyl or N(R20)(R21), wherein R20 and R21 together are C1-6alkyl-Y—C1-6alkyl, preferably C1-3alkyl-Y—C1-3alkyl, thereby forming a ring.
In certain preferred embodiments, L is C═O, Q is absent, and R11 is selected from (R12O)(R13O)P(═O)O—C1-8alkyl-, (R14)2NC1-8alkyl, (R14)3N+(CH2)n—, and heterocyclyl-M-. In certain such embodiments, R11 is —C1-8alkylN(R14)2 or —C1-8alkylN+(R14)3, where R14 is C1-6alkyl. In certain other such embodiments, R11 is heterocyclylM-, where heterocyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.
In certain embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH and R11 is selected from C1-6alkyl, cycloalkyl-M, C1-6araalkyl, and C1-6heteroaraalkyl. In other embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH, and R11 is C1-6alkyl, where C1-6alkyl is selected from methyl, ethyl, and isopropyl. In further embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH and R11 is C1-6aralkyl, where aralkyl is phenylmethyl. In other embodiments, L is C═O, R10 is C1-6alkyl, Q is selected from O and NH, and R11 is C1-6heteroaralkyl, where heteroaralkyl is (4-pyridyl)methyl.
In certain embodiments, L is absent or is C═O, and R10 and R11 together are C1-6alkyl-Y—C1-6alkyl, C1-6alkyl-ZA-C1-6alkyl, or C1-6alkyl-A, thereby forming a ring. In certain preferred embodiments, L is C═O, Q and Y are absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L and Q are absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L is C═O, Q is absent, Y is selected from NH and N—C1-6alkyl, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L is C═O, Y is absent, and R10 and R11 together are C1-3alkyl-Y—C1-3alkyl. In another preferred embodiment, L and A are C═O, and R10 and R11 together are C1-2alkyl-ZA-C1-2alkyl. In another preferred embodiment, L and A are C═O and R10 and R11 together are C2-3alkyl-A.
In certain embodiments, R16 is (R17O)(R18O)P(═O)W—. In certain such embodiments, D, V, K, and W are absent. In other such embodiments, V and K are absent, D is C1-8alkyl, and W is O. In yet other such embodiments, D is C1-8alkyl, K is C═O, and V and W are O.
In certain embodiments, R16 is R17GB—. In preferred embodiments, B is C═O, G is O, D is C1-8alkyl, V is O, and K is C═O.
In certain embodiments, R16 is heterocyclyl-. In preferred such embodiments, D is C1-8alkyl. In certain such embodiments, V is O, K is C═O, and heterocyclyl is oxodioxolenyl. In other such embodiments, V is absent, K is absent or is C═O, and heterocyclyl is N(R20)(R21), where R20 and R21 together are J-T-J, J-WB-J, or B-J-T-J, T is absent or is selected from O, NR17, S, SO, SO2, CHOR19, CHCO2R17, C═O, CF2, and CHF, and J is absent or is C1-3alkyl.
In certain embodiments, R16 is (R19)2N— or (R19)3N+—, and preferably V is absent. In preferred such embodiments, D is C1-8alkyl and K is absent or C═O. In certain embodiments where V is absent and R16 is (R19)2N—, D is absent K is absent or is C═O, preferably K is C═O.
In certain embodiments, R16 is R19SO2GBG-. In preferred such embodiments, B is C═O, D, V, and K are absent, and G is NH or NC1-6alkyl.
In certain embodiments, R16 is R17GBC1-8alkyl-. In preferred embodiments, B is C═O, G is O, and the C1-8alkyl moiety is optionally substituted with OH, C1-8alkyl (optionally substituted with halogen, preferably fluorine), C1-8alkylW, aryl, heteroaryl, carbocyclyl, heterocyclyl, and C1-6aralkyl. In certain such embodiments, the C1-8alkyl moiety is an unsubstituted, mono-, or disubstituted C1alkyl.
In certain embodiments, the product of the coupling reaction of a compound of the amino acid keto-epoxide or keto-aziridine with a compound of formula (III) is a compound having a structure of formula (IV)
wherein
In certain embodiments, the chain of amino acids has a structure of formula (V) or (VI) or a pharmaceutically acceptable salt thereof
wherein
In certain embodiments, L is selected from C═O, C═S, and SO2, preferably SO2 or C═O.
In certain embodiments, R10 is selected from hydrogen, OH, C1-6aralkyl, and C1-6alkyl, preferably hydrogen.
In certain embodiments, R11 is selected from hydrogen, C1-6alkenyl, Ar—Y—, carbocyclyl, and heterocyclyl.
In certain embodiments, R5 and R6 are each independently selected from C1-6alkyl, C1-6hydroxyalkyl, and C1-6aralkyl. In preferred such embodiments, R5 is C1-6alkyl and R6 is C1-6aralkyl. In more preferred such embodiments, R5 is isobutyl and R6 is phenylmethyl.
In certain embodiments, R10 is hydrogen, L is C═O or SO2, R11 is Ar—Y—, and each Ar is independently selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like. In certain such embodiments, Ar may be substituted with Ar-Q-, where Q is selected from a direct bond, —O—, and C1-6alkyl. In certain other such embodiments where Z is C1-6alkyl, Z may be substituted, preferably with Ar, e.g., phenyl.
In certain embodiments, R10 is hydrogen, Z is absent, L is C═O or SO2, and R11 is selected from Ar—Y and heterocyclyl. In certain preferred such embodiments, heterocyclyl is selected from chromonyl, chromanyl, morpholino, and piperidinyl. In certain other preferred such embodiments, Ar is selected from phenyl, indolyl, benzofuranyl, naphthyl, quinolinyl, quinolonyl, thienyl, pyridyl, pyrazyl, and the like.
In certain embodiments, R10 is hydrogen, L is C═O or SO2, Z is absent, and R11 is C1-6alkenyl, where C1-6alkenyl is a substituted vinyl group where the substituent is preferably an aryl or heteroaryl group, more preferably a phenyl group optionally substituted with one to four substituents.
In certain embodiments, R12 is selected from hydrogen and C1-6alkyl. In certain preferred such embodiments, R12 is selected from hydrogen and methyl. In more preferred such embodiments, R12 is hydrogen.
In certain preferred embodiments, the chain of amino acids has a structure of formula (VII)
X is COOH or an activated form thereof, preferably X is COOH, COCl, or CON(Me)(OMe), most preferably X is COOH or COCl;
R5, R6, and R7 are independently selected from C1-6alkyl, C1-6hydroxyalkyl, C1-6alkoxyalkyl, aryl, and C1-6aralkyl, each of which is optionally substituted with a group selected from amide, amine, carboxylic acid or a pharmaceutically acceptable salt thereof, carboxyl ester, thiol, and thioether, preferably R6 is C1-6alkyl and R5 and R7 are C1-6aralkyl, most preferably, R6 is isobutyl, R5 is 2-phenylethyl, and R7 is phenylmethyl;
R9 is a further chain of amino acids, hydrogen, C1-6acyl, a protecting group, aryl, or heteroaryl, where substituents include halogen, carbonyl, nitro, hydroxy, aryl, and C1-5alkyl, preferably R9 is C1-6acyl, most preferably R9 is acetyl.
The terms “amine” and “amino” are art-recognized and refer to both unsubstituted and substituted amines and salts thereof, e.g., a moiety that can be represented by the general formulae:
wherein R9, R10 and R10′ each independently represent a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8, or R9 and R10 taken together with the N atom to which they are attached complete a heterocycle having from 4 to 8 atoms in the ring structure; R8 represents an aryl, a cycloalkyl, a cycloalkenyl, a heterocyclyl or a polycyclyl; and m is zero or an integer from 1 to 8. In preferred embodiments, only one of R9 or R10 can be a carbonyl, e.g., R9, R10, and the nitrogen together do not form an imide. In even more preferred embodiments, R9 and R10 (and optionally R10′) each independently represent a hydrogen, an alkyl, an alkenyl, or —(CH2)m—R8. In certain embodiments, the amino group is basic, meaning the conjugate acid has a pKa>7.00.
The terms “amide” and “amido” are art-recognized as an amino-substituted carbonyl and includes a moiety that can be represented by the general formula:
wherein R9 and R10 are as defined above for “amine” or “amino”. Preferred embodiments of the amide will not include imides which may be unstable.
The term “aryl” as used herein includes 5-, 6-, and 7-membered substituted or unsubstituted single-ring aromatic groups in which each atom of the ring is carbon. The term “aryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Aryl groups include benzene, naphthalene, phenanthrene, phenol, aniline, and the like.
The terms “carbocycle” and “carbocyclyl”, as used herein, refer to a non-aromatic substituted or unsubstituted ring in which each atom of the ring is carbon. The terms “carbocycle” and “carbocyclyl” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is carbocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls.
The term “carbonyl” is art-recognized and includes such moieties as can be represented by the general formula:
wherein X is a bond or represents an oxygen or a sulfur, and R11 represents a hydrogen, an alkyl, an alkenyl, —(CH2)m—R8 or a pharmaceutically acceptable salt, R11′ represents a hydrogen, an alkyl, an alkenyl or —(CH2)m—R8, where m and R8 are as defined above. Where X is an oxygen and R11 or R11′ is not hydrogen, the formula represents an “ester”. Where X is an oxygen, and R11 is a hydrogen, the formula represents a “carboxylic acid”.
As used herein, “enzyme” can be any partially or wholly proteinaceous molecule which carries out a chemical reaction in a catalytic manner. Such enzymes can be native enzymes, fusion enzymes, proenzymes, apoenzymes, denatured enzymes, farnesylated enzymes, ubiquitinated enzymes, fatty acylated enzymes, gerangeranylated enzymes, GPI-linked enzymes, lipid-linked enzymes, prenylated enzymes, naturally-occurring or artificially-generated mutant enzymes, enzymes with side chain or backbone modifications, enzymes having leader sequences, and enzymes complexed with non-proteinaceous material, such as proteoglycans, proteoliposomes. Enzymes can be made by any means, including natural expression, promoted expression, cloning, various solution-based and solid-based peptide syntheses, and similar methods known to those of skill in the art.
The term “C1-6heteroaralkyl”, as used herein, refers to a C1-6alkyl group substituted with a heteroaryl group.
The terms “heteroaryl” includes substituted or unsubstituted aromatic 5- to 7-membered ring structures, more preferably 5- to 6-membered rings, whose ring structures include one to four heteroatoms. The term “heteroaryl” also includes polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heteroaromatic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heteroaryl groups include, for example, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, triazole, pyrazole, pyridine, pyrazine, pyridazine and pyrimidine, and the like.
The term “heteroatom” as used herein means an atom of any element other than carbon or hydrogen. Preferred heteroatoms are nitrogen, oxygen, phosphorus, and sulfur.
The terms “heterocyclyl” or “heterocyclic group” refer to substituted or unsubstituted non-aromatic 3- to 10-membered ring structures, more preferably 3- to 7-membered rings, whose ring structures include one to four heteroatoms. The term terms “heterocyclyl” or “heterocyclic group” also include polycyclic ring systems having two or more cyclic rings in which two or more carbons are common to two adjoining rings wherein at least one of the rings is heterocyclic, e.g., the other cyclic rings can be cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls. Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.
The term “C1-6hydroxyalkyl” refers to a C1-6alkyl group-substituted with a hydroxy group.
As used herein, the term “inhibitor” is meant to describe a compound that blocks or reduces an activity of an enzyme (for example, inhibition of proteolytic cleavage of standard fluorogenic peptide substrates such as Suc-LLVY-AMC, Box-LLR-AMC and Z-LLE-AMC, inhibition of various catalytic activities of the 20S proteasome). An inhibitor can act with competitive, uncompetitive, or noncompetitive inhibition. An inhibitor can bind reversibly or irreversibly, and therefore the term includes compounds that are suicide substrates of an enzyme. An inhibitor can modify one or more sites on or near the active site of the enzyme, or it can cause a conformational change elsewhere on the enzyme.
As used herein, the term “peptide” includes not only standard amide linkage with standard α-substituents, but commonly utilized peptidomimetics, other modified linkages, non-naturally occurring side chains, and side chain modifications, as detailed below.
The terms “polycyclyl” or “polycyclic” refer to two or more rings (e.g., cycloalkyls, cycloalkenyls, cycloalkynyls, aryls, heteroaryls, and/or heterocyclyls) in which two or more carbons are common to two adjoining rings, e.g., the rings are “fused rings”. Each of the rings of the polycycle can be substituted or unsubstituted.
The term “preventing” is art-recognized, and when used in relation to a condition, such as a local recurrence (e.g., pain), a disease such as cancer, a syndrome complex such as heart failure or any other medical condition, is well understood in the art, and includes administration of a composition which reduces the frequency of, or delays the onset of, symptoms of a medical condition in a subject relative to a subject which does not receive the composition. Thus, prevention of cancer includes, for example, reducing the number of detectable cancerous growths in a population of patients receiving a prophylactic treatment relative to an untreated control population, and/or delaying the appearance of detectable cancerous growths in a treated population versus an untreated control population, e.g., by a statistically and/or clinically significant amount. Prevention of an infection includes, for example, reducing the number of diagnoses of the infection in a treated population versus an untreated control population, and/or delaying the onset of symptoms of the infection in a treated population versus an untreated control population. Prevention of pain includes, for example, reducing the magnitude of, or alternatively delaying, pain sensations experienced by subjects in a treated population versus an untreated control population.
The term “prophylactic or therapeutic” treatment is art-recognized and includes administration to the host of one or more of the subject compositions. If it is administered prior to clinical manifestation of the unwanted condition (e.g., disease or other unwanted state of the host animal) then the treatment is prophylactic, (i.e., it protects the host against developing the unwanted condition), whereas if it is administered after manifestation of the unwanted condition, the treatment is therapeutic, (i.e., it is intended to diminish, ameliorate, or stabilize the existing unwanted condition or side effects thereof).
The term “stereoselective” is art-recognized and refers to reactions in which one diastereomer (or one enantiomeric pair of diastereomers) is formed or destroyed in considerable preference to others that might have been formed or destroyed.
The term “substituted” refers to moieties having substituents replacing a hydrogen on one or more carbons of the backbone. It will be understood that “substitution” or “substituted with” includes the implicit proviso that such substitution is in accordance with permitted valence of the substituted atom and the substituent, and that the substitution results in a stable compound, e.g., which does not spontaneously undergo transformation such as by rearrangement, cyclization, elimination, etc. As used herein, the term “substituted” is contemplated to include all permissible substituents of organic compounds. In a broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, the heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valences of the heteroatoms. Substituents can include, for example, a halogen, a hydroxyl, a carbonyl (such as a carboxyl, an alkoxycarbonyl, a formyl, or an acyl), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an alkoxyl, a phosphoryl, a phosphate, a phosphonate, a phosphinate, an amino, an amido, an amidine, an imine, a cyano, a nitro, an azido, a sulfhydryl, an alkylthio, a sulfate, a sulfonate, a sulfamoyl, a sulfonamido, a sulfonyl, a heterocyclyl, an aralkyl, or an aromatic or heteroaromatic moiety. It will be understood by those skilled in the art that the moieties substituted on the hydrocarbon chain can themselves be substituted, if appropriate.
A “therapeutically effective amount” of a compound with respect to the subject method of treatment, refers to an amount of the compound(s) in a preparation which, when administered as part of a desired dosage regimen (to a mammal, preferably a human) alleviates a symptom, ameliorates a condition, or slows the onset of disease conditions according to clinically acceptable standards for the disorder or condition to be treated or the cosmetic purpose, e.g., at a reasonable benefit/risk ratio applicable to any medical treatment.
As used herein, the term “treating” or “treatment” includes reversing, reducing, or arresting the symptoms, clinical signs, and underlying pathology of a condition in manner to improve or stabilize a subject's condition.
The phrase “pharmaceutically acceptable” is employed herein to refer to those ligands, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
The term “pharmaceutically acceptable salt” refers to the relatively non-toxic, inorganic and organic acid addition salts of the inhibitor(s). These salts can be prepared in situ during the final isolation and purification of the inhibitor(s), or by separately reacting a purified inhibitor(s) in its free base form with a suitable organic or inorganic acid, and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, tosylate, citrate, maleate, flimarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts, and amino acid salts, and the like. (See, for example, Berge et al. (1977) “Pharmaceutical Salts”, J. Pharm. Sci. 66: 1-19.)
In other cases, the inhibitors useful in the methods of the present invention may contain one or more acidic functional groups and, thus, are capable of forming pharmaceutically acceptable salts with pharmaceutically acceptable bases. The term “pharmaceutically acceptable salts” in these instances refers to the relatively non-toxic inorganic and organic base addition salts of an inhibitor(s). These salts can likewise be prepared in situ during the final isolation and purification of the inhibitor(s), or by separately reacting the purified inhibitor(s) in its free acid form with a suitable base, such as the hydroxide, carbonate, or bicarbonate of a pharmaceutically acceptable metal cation, with ammonia, or with a pharmaceutically acceptable organic primary, secondary, or tertiary amine. Representative alkali or alkaline earth salts include the lithium, sodium, potassium, calcium, magnesium, and aluminum salts, and the like. Representative organic amines useful for the formation of base addition salts include ethylamine, diethylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, and the like (see, for example, Berge et al., supra).
Exemplification
Synthesis of (B) and (C)
To a 0° C. solution of (A) (10.57 g, 36.52 mmol), [prepared as described in Bioorg. Med. Chem. Lett. 1999, 9, 2283-88] in 400 mL of MeOH was added CeCl3-7H2O (16.33 g, 43.82 mmol). The solution was stirred under an atmosphere of argon until the CeCl3-7H2O was completely dissolved. To this solution was added NaBH4 (1.65 g, 43.82 mmol) in 10 portions over 2 minutes. The reaction was stirred under an atmosphere of argon at 0° C. for 6 hours, at which point the mixture became milky white. The reaction was quenched at 0° C. with approximately 5 mL of glacial HOAc and after 30 minutes of additional stirring at 0° C. the mixture became clear. The volatiles were removed under reduced pressure and the remaining oil taken up in EtOAc (300 mL). The organic layer was washed with water (2×200 mL), brine (2×200 mL) and dried over MgSO4. The MgSO4 was removed by filtration and the volatiles removed under reduced pressure. Purification by flash chromatography afforded (B) and (C) as a 9:1 mixture (10.5 g). Rf=0.21 (5:1 hexanes/EtOAc); 1H NMR (300 MHz, CDCl3): (B) δ 7.38-7.25 (m, 5 H), 5.18-4.82 (m, 5 H), 4.17 (br s, 1 H), 3.91 (m, 1 H), 1.99 (br s, 1 H), 1.78 (s, 3 H), 1.64 (m, 1 H), 1.26 (m, 2 H), 0.91 (m, 6 H).
Several reaction conditions were examined for the conversion of (A) to (B) and (C) as shown in table (1). In all cases the starting enone was completely consumed.
Synthesis of (D) and (E)
To a 0° C. solution of a 9/1 mixture of (B) and (C) (10.56 g, 36.24 mmol) in 360 mL of dry dichloromethane under an atmosphere of argon was added VO(acac)2 (0.289 g, 1.09 mmol). To this solution was added t-BuOOH (5.5 M solution in decane, 13.2 mL, 72.5 mmol). Upon the addition of the t-BuOOH the color of the reaction turned from a bright green to a deep red. The reaction was removed from the ice-water bath and allowed to warm to room temperature while stirring for 6 hours. At this time the color of the reaction had become light yellow and the reaction was deemed complete by TLC. The reaction mixture was filtered through a plug of Celite, transferred to a separatory funnel, and washed with ½ saturated NaHCO3 (2×200 mL) and the aqueous layer extracted with dichloromethane (2×100 mL). The organic layers were combined and washed with water (2×200 mL) and brine (2×200 mL) and dried over MgSO4. The MgSO4 was removed by filtration and the volatiles removed under reduced pressure to give a 9/1 mixture of (D) and (E) (10.0 g). Rf=0.18 (3:1 hexanes/EtOAc); 1H NMR (300 MHz, CDCl3): (D) δ 7.38-7.31 (m, 5 H), 5.15-4.98 (m, 3 H), 3.99 (m, 1 H), 3.87 (br s, 1 H), 2.97 (d, J=4.69 Hz, 1 H), 2.64 (d, J=4.69 Hz, 1 H), 2.15 (br s, 1 H), 1.65 (m, 1 H), 1.47 (m, 1 H), 1.37 (s, 3 H), 1.09 (m, 1 H), 0.92 (m, 6 H).
Alternate Synthesis of (D) and (E)
To a solution of a 9/1 mixture of (B) and (C) (0.34 mmol, 0.10 g) in DCM (5 mL) was added mCPBA (0.52 mmol, 0.089 g) and the mixture stirred for 5 hours. The mixture was diluted with sat. NaHCO3 (5 mL) and the layers separated. The aqueous layer was extracted with DCM (2×5mL) and the layers combined, washed with sat. NaHCO3 (3×15 mL), water (1×10 mL), brine (1×15 mL) and dried over MgSO4. The MgSO4 was removed by filtration and the volatiles removed under reduced pressure to give a 9/1 mixture of (D) and (E) (0.097 g).
Synthesis of Compounds 1 and 2
To 225 mL of dry dichloromethane was added oxalyl chloride (22.85 g, 15.7 mL, 180 mmol) and the mixture cooled to −78° C. under an atmosphere of argon. To the cooled solution was added drop wise, DMSO (16.88 g, 15.33 mL, 216 mmol), freshly distilled from CaH2, dissolved in 60 mL of dry dichloromethane. The temperature of the reaction was monitored during the addition of the DMSO and the addition rate adjusted to keep the temperature below −65° C. requiring approximately 45 minutes. Ten minutes after the addition of the DMSO, a 9/1 mixture of (D) and (E) (10.0 g, 32.5 mmol) dissolved in 75 mL of dry dichloromethane was added drop wise. The reaction was stirred at −78° C. for 30 minutes and triethylamine (36.4 g, 50.6 mL, 360 mmol) was added drop wise and the reaction mixture placed in a 0° C. ice bath. The reaction was maintained at 0° C. for 30 minutes at which time the reaction was deemed complete by TLC. The reaction was quenched with 20 mL of H2O mixed with 80 mL of dichloromethane. The muddy brown mixture became clear brown after approximately 10 minutes of stirring. The layers were separated and the aqueous layer extracted with CH2Cl2 (2×50 mL). The organic layers were combined washed with brine (2×100 mL) and dried over MgSO4. The MgSO4 was removed by filtration and the volatiles removed under reduced pressure. Purification by flash chromatography gave compound 1 (3.18 g). Rf=0.26 (5:1 hexanes/EtOAc); 1H NMR (300 MHz, CDCl3): δ 7.39-7.22 (m, 5 H), 5.11 (d, J=9.4 Hz, 1 H), 5.07 (d, J=15.5 Hz, 1 H), 5.03 (d, J=15.2 Hz, 1 H), 4.40 (ddd, J=10.3, 8.8, 2.9 Hz, 1 H), 3.27 (d, J=5.0, 1 H), 2.90 (d, J=5.0 Hz, 1 H), 1.71 (m, 1 H), 1.47 (s, 3 H), 1.21 (m, 2 H), 0.97 (d, J=6.5 Hz, 3 H), 0.93 (d, J=6.7 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ 201.9, 156.2, 136.1, 128.5, 128.1, 128.0, 66.9, 52.2, 51.8, 40.5, 25.0, 23.4, 21.2, 16.7. Compound 2: Rf=0.15 (5:1 hexanes/EtOAc); 1H NMR (300 MHz, CDCl3): δ 7.39-7.25 (m, 5 H), 5.09 (m, 3 H), 4.66 (ddd, J=7.3, 7.0, 7.0 Hz, 1 H), 3.03 (d, J=4.7 Hz, 1 H), 2.86 (d, J=5.0 Hz, 1 H), 1.70 (m, 1 H), 1.55 (s, 3 H), 1.37 (m, 2 H), 0.97 (d, J=6.5 Hz, 3 H), 0.91 (d, J=6.7 Hz, 3 H); 13C NMR (75 MHz, CDCl3): δ 207.4, 155.7, 136.1, 128.4, 128.1, 128.0, 66.9, 58.6, 53.0, 52.7, 41.0, 24.7, 23.2, 21.4, 17.4.
Alternate (A) Synthesis of 1 and 2
To a solution of a 9/1 mixture of (D) and (E) (0.29 g, 0.95 mmol) in DCM (10 mL) was added NMO (0.17 g, 1.43 mmol), crushed 4Å molecular sieves (0.76 g) and the reaction was stirred for 15 minutes. TPAP (0.02 g, 0.05 mmol) was added to the mixture and the reaction was stirred for 36 hours. The reaction was diluted with hexanes (15 mL) and filtered through a plug of silica gel, washing with (5:1 hexanes/EtOAc, 50 mL). The volatiles were removed under reduced pressure and the crude material purified by flash chromatography affording 1 (0.138 g).
Alternate (B) Synthesis of 1 and 2
To a 5° C. solution of Dess-Martin Periodinane (6.95 g, 16.4 mmol) in 80 mL DMSO was added a 4/1 mixture of (D) and (E) (2.52 g, 8.20 mmol) as a DMSO solution (15 mL). The mixture was placed under an atmosphere of argon and allowed to warm to room temperature while stirring overnight. When complete, a white precipitate had formed and the reaction was cooled in an ice-bath and diluted with 100 mL sat. NaHCO3. The mixture was further diluted with 400 mL of EtOAc and the solids removed by filtering through a plug of Celite. The mixture was transferred to a separatory funnel and the layers separated. The aqueous layer was extracted with EtOAc (2×200 mL) and the organic layers combined, washed with H2O (3×100 mL), brine (1×400 mL) and dried over Na2SO4. The Na2SO4 was removed by filtration and the volatiles removed under reduced pressure to give a light yellow oil. Purification by flash chromatography afforded 1 (1.0 g) and 2 (0.20 g).
Synthesis of (G) and (H)
Compounds (G) and (H) were obtained by following the same procedure for the conversion of (A) to (B) and (C) but substituting (F) for (A).
Synthesis of (I) and (J)
Compounds (I) and (J) were obtained by following the same procedure for the conversion of (B) and (C) to (D) and (E) but substituting (G) and (H) for (B) and (C) respectively.
Synthesis of Compounds 3 and 4
Compounds 3 and 4 were obtained by following the same procedure for the conversion of (D) and (E) to compounds 1 and 2 respectively but substituting (I) and (J) for (D) and (E) respectively. The 1H and 13C NMR spectra of compounds 3 and 4 were identical to compounds 1 and 2 respectively.
Equivalents
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the compounds and methods of use thereof described herein. Such equivalents are considered to be within the scope of this invention and are covered by the following claims.
All of the above-cited references and publications are hereby incorporated by reference.
This application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/572072 filed on May 17, 2004 and is a continuation-in-part of International Application Ser. No. ______ (entitled “Compounds for Enzyme Inhibition”) filed on May 9, 2005. International Application Serial No. ______ (entitled “Compounds for Enzyme Inhibition”) filed on May 9, 2005 claims the benefit of U.S. Provisional Patent Application Ser. No. 60/569885 filed on May 10, 2004 and U.S. Provisional Patent Application Ser. No. 60/610040 filed on Sep. 14, 2004. The teachings of all of the referenced applications are incorporated by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| 60572072 | May 2004 | US | |
| 60569885 | May 2004 | US | |
| 60610040 | Sep 2004 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US05/16335 | May 2005 | US |
| Child | 11131688 | May 2005 | US |
